Frequency of CYP2C9 (*2, *3 and IVS8‑109A>T) allelic variants, and their clinical implications, among Mexican patients with diabetes mellitus type 2 undergoing treatment with glibenclamide and metformin-Reference-Cited by-同舟云学术

Frequency of CYP2C9 (*2, *3 and IVS8‑109A>T) allelic variants, and their clinical implications, among Mexican patients with diabetes mellitus type 2 undergoing treatment with glibenclamide and metformin

Published:2019-04-04 Issue: Volume: Page:
ISSN:2049-9434
Container-title:Biomedical Reports
language:
Short-container-title:biom rep

Author:

Cuautle‑Rodr�guez Patricia¹,Rodr�guez‑Rivera Nidia¹,De Andr�s Fernando²,Castillo‑N�jera Fernando³,Llerena Adri�n²,Molina‑Guarneros Juan¹

Affiliation:

1. Departamento de Farmacolog�a, Facultad de Medicina, Universidad Nacional Aut�noma de M�xico, Ciudad de M�xico 04510, M�xico

2. Centro de Investigaci�n Cl�nica �rea de Badajoz, SES Hospital Universitario, Universidad de Extremadura, Badajoz 06071, Spain

3. Centro de Salud T‑III Portales, Servicios de Salud Gobierno de la Ciudad de M�xico, Ciudad de M�xico 03660, M�xico

Publisher

Spandidos Publications

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glycated Hemoglobin is a Biomarker of Renal Failure in Diabetic Patients;Journal of Internal Medicine and Emergency Research;2022-06-30

2. Pharmacogenetics of Metformin Transporters Suggests No Association with Therapeutic Inefficacy among Diabetes Type 2 Mexican Patients;Pharmaceuticals;2022-06-22

3. Pharmacogenomics of sulfonylureas in type 2 diabetes mellitus; a systematic review;Journal of Diabetes & Metabolic Disorders;2021-12-01

4. rs622342 in SLC22A1, CYP2C9*2 and CYP2C9*3 and Glycemic Response in Individuals with Type 2 Diabetes Mellitus Receiving Metformin/Sulfonylurea Combination Therapy: 6-Month Follow-Up Study;Journal of Personalized Medicine;2020-06-20